Analyst Reco. Gilead Sciences, Inc.

Equities

GILD

US3755581036

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
65.42 ^USD	+0.23%		-2.29%	-19.24%

Apr. 26	TD Cowen Adjusts Price Target on Gilead Sciences to $85 From $90	MT
Apr. 26	Jefferies Adjusts Gilead Sciences' Price Target to $80 From $95	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

TD Cowen Adjusts Price Target on Gilead Sciences to $85 From $90	Apr. 26	MT
Jefferies Adjusts Gilead Sciences' Price Target to $80 From $95	Apr. 26	MT
RBC Capital Adjusts Gilead Sciences' Price Target to $74 From $76	Apr. 26	MT
Morgan Stanley Adjusts Price Target on Gilead Sciences to $78 From $80	Apr. 26	MT
North American Morning Briefing : More Tech -2-	Apr. 25	DJ
HSBC Upgrades Gilead Sciences to Hold From Reduce, Price Target is $69	Apr. 24	MT
Argus Cuts Price Target on Gilead Sciences to $75 From $85	Apr. 23	MT
Cantor Fitzgerald Adjusts Gilead Sciences' Price Target to $75 From $78, Maintains Neutral Rating	Apr. 22	MT
BMO Capital Adjusts Price Target on Gilead Sciences to $80 From $89	Apr. 19	MT
Leerink Partners Adjusts Gilead Sciences Price Target to $74 From $79	Apr. 19	MT
UBS Adjusts Gilead Sciences Price Target to $75 From $81, Maintains Neutral Rating	Apr. 17	MT
Goldman Sachs Adjusts Gilead Sciences Price Target to $73 From $76	Apr. 15	MT
Morgan Stanley Cuts Price Target on Gilead Sciences to $80 From $83, Keeps Equalweight Rating	Apr. 09	MT
Wells Fargo Cuts Price Target on Gilead Sciences to $78 From $84, Keeps Equalweight Rating	Mar. 04	MT
Mizuho Securities Cuts Price Target on Gilead Sciences to $90 From $101, Maintains Buy Rating	Feb. 22	MT
Truist Securities Downgrades Gilead Sciences to Hold From Buy, Cuts Price Target to $82 From $91	Feb. 22	MT
ANALYST RECOMMENDATIONS : Coinbase, Fortinet, Nike, Chipotle, Nvidia...	Feb. 16
RBC Trims Price Target on Gilead Sciences to $75 From $76, Keeps Sector Perform Rating	Feb. 14	MT
B. Riley Downgrades CymaBay Therapeutics to Neutral From Buy on Heels of Announced Sale to Gilead Sciences, Raises PT to $32.50 From $29	Feb. 13	MT
Oppenheimer Cuts Gilead Sciences Price Target to $105 From $115, Maintains Outperform Rating	Feb. 12	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Gilead Sciences, Inc.

Equities

GILD

US3755581036

Analyst Reco.

Filters